Gossamer Bio, Inc. (GOSS) Financial Statements
Gossamer Bio, Inc. (GOSS) reported trailing twelve-month revenue of $53.3M (up 32.4% year on year) and net income of -$125.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$162.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GOSSGossamer Bio, Inc.Follow GOSS — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 114.7 | 48.5 | 53.3 | |
| Research & development | 138.5 | 174.1 | 164.0 | |
| Operating income | -59.9 | -170.7 | -166.1 | |
| Pre-tax income | -55.6 | -170.5 | — | |
| Income tax | 0.9 | -0.1 | — | |
| Net income | -56.5 | -170.4 | -125.2 | |
| Diluted EPS ($) | -0.25 | -0.75 | -0.52 | |
| Diluted shares (mn) | 226.2 | 228.5 | — |
USD millions · SEC XBRL
Gossamer Bio, Inc. — questions
- What is Gossamer Bio, Inc.'s revenue?
- $53.3M over the twelve months to 2026-06-30, up 32.4% year on year, from its 10-Q and 10-K filings.
- What is Gossamer Bio, Inc.'s net income?
- -$125.2M over the twelve months to 2026-06-30.
- What is Gossamer Bio, Inc.'s free cash flow?
- -$162.6M over the twelve months to 2026-06-30.
- What are Gossamer Bio, Inc.'s diluted earnings per share?
- $-0.52 over the twelve months to 2026-06-30.
Every figure on this page comes from Gossamer Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.